Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Summary

This phase I trial is studying the side effects and best dose of temsirolimus when given with imatinib mesylate in treating patients with chronic myelogenous leukemia. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus with imatinib mesylate may kill more cancer cells

Timeline

Start

2005-04

Primary completion

2010-06

Completion

—

Drugs

Indications